Blog
Blog
2021 Outlook: Challenges, opportunities facing US TV, radio stations
The first era of SaaS ends: Best of breed was prelude to systems of delivery
16 Mar, 2021 Author Joseph WilliamsStefen Joshua Rasay
Wall Street has fallen in love with blank-check companies, which, in turn, love the technology, media and telecom markets.
This is the first installment of a three-part series focused on tech SPACs. The full series can be found here:
Tech and SPACs: A dance of Wall Street darlings
Tech and SPACs: Too much of two good things
Tech and SPACs: Feeding the frenzy
Blank-check firms, formally known as special purpose acquisition companies, combine a reverse merger with an IPO. A shell company launches an IPO with the expressed intent of using the funds to acquire an unspecified operating company. This allows the company to access public capital without having to undertake the highly regulated and scrutinized IPO process.
2 SPAC Stocks That Could Be 10-Baggers fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference
DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT.
On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
The webcast will be available for replay for 30 days following the presentation and can be accessed at www.Humacyte.com and https://wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimer9&page=huma&url=https://wsw.com/webcast/oppenheimer9/huma/2712391.
Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021 yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.